Madrigal Pharmaceuticals, Inc. (MDGL) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$539.73
Price Target
$705.67
Target Range
$527.00 — $964.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-42.0x
Forward PEG—
Implied Growth+63.8%
Median Target$640.00
Analyst Spread61.9%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$527
-2.4%
Consensus
$706
+30.7%
Bull Case
$964
+78.6%
MDGL Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Madrigal Pharmaceuticals, Inc. (MDGL) has a Wall Street consensus price target of $705.67, based on estimates from 23 covering analysts. With the stock currently trading at $539.73, this represents a potential upside of +30.7%. The company has a market capitalization of $12.38B.
Analyst price targets range from a low of $527.00 to a high of $964.00, representing a 62% spread in expectations. The median target of $640.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 20 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, MDGL trades at a trailing P/E of -42.0x. Analysts expect EPS to grow +63.8% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+57.3%
Avg Forward P/E35.8x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 AKROAkero Therapeutics, Inc. | $4.5B | $54.65 | $48.40 | -11.4% | Buy | — | 14 |
 HIMSHims & Hers Health, Inc. | $6.9B | $26.88 | $29.67 | +10.4% | Hold | 53.9x | 19 |
 ELVNEnliven Therapeutics, Inc. | $2.4B | $41.20 | $43.33 | +5.2% | Buy | — | 6 |
 TERNTerns Pharmaceuticals, Inc. | $4.6B | $52.97 | $55.56 | +4.9% | Buy | — | 16 |
 GPCRStructure Therapeutics Inc. | $2.4B | $40.84 | $114.75 | +181.0% | Buy | — | 14 |
 NVCRNovoCure Limited | $1.9B | $16.50 | $33.50 | +103.1% | Buy | — | 15 |
 HALOHalozyme Therapeutics, Inc. | $7.8B | $66.35 | $78.33 | +18.1% | Buy | 8.2x | 27 |
 ARWRArrowhead Pharmaceuticals, Inc. | $11.1B | $79.14 | $81.22 | +2.6% | Buy | — | 20 |
 ALNYAlnylam Pharmaceuticals, Inc. | $40.4B | $303.00 | $445.67 | +47.1% | Buy | 45.2x | 52 |
 VKTXViking Therapeutics, Inc. | $3.7B | $32.28 | $100.75 | +212.1% | Buy | — | 24 |
Upside Potential Comparison
VKTXGPCRNVCRALNYHALOHIMSELVNTERNFull MDGL Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See MDGL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MDGL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MDGL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMDGL — Frequently Asked Questions
Quick answers to the most common questions about buying MDGL stock.
What is the MDGL stock price target for 2026?
The consensus Wall Street price target for MDGL is $705.67, representing 30.7% upside from the current price of $539.73. With 23 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is MDGL a buy, sell, or hold?
MDGL has a consensus rating of "Buy" based on 23 Wall Street analysts. The rating breakdown is predominantly bullish, with 20 Buy/Strong Buy ratings. The consensus 12-month price target of $705.67 implies 30.7% upside from current levels.
Is MDGL stock overvalued or undervalued?
MDGL's current price is $539.73 with a consensus target of $705.67 (30.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can MDGL stock go?
The most bullish Wall Street analyst has a price target of $964 for MDGL, while the most conservative target is $527. The consensus of $705.67 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover MDGL stock?
MDGL is well covered by analysts, with 23 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 20 have Buy ratings, 2 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the MDGL stock forecast?
The 12-month MDGL stock forecast based on 23 Wall Street analysts shows a consensus price target of $705.67, with estimates ranging from $527 (bear case) to $964 (bull case). The median consensus rating is "Buy".
Should I buy MDGL stock?
Wall Street analysts are very optimistic on MDGL, with a "Buy" consensus rating and $705.67 price target (30.7% upside). 20 of 23 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do MDGL price targets vary so much?
MDGL analyst price targets range from $527 to $964, a 62% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $705.67 consensus represents the middle ground.